Home World Kexing’s global supply of new crown vaccine exceeds 2.2 billion doses, nearly half of the world’s supply comes from Chinese companies-qianlong.com.cn

Kexing’s global supply of new crown vaccine exceeds 2.2 billion doses, nearly half of the world’s supply comes from Chinese companies-qianlong.com.cn

by admin

Source Title: The global supply of Coxing’s new crown vaccine exceeds 2.2 billion doses. Nearly half of the global supply comes from Chinese companies

Guangming News Nearly half of the world’s new crown vaccine supply comes from Chinese companies. On November 16, CGTN cited data from the British life science information and analysis company Airfinity. The two major vaccine suppliers from China, Kexing and Sinopharm, have supplied more than 4 billion doses of COVID-19 vaccine, accounting for approximately one of the total global vaccine supply. 45%.

On November 20, Kexing released its latest global supply and vaccination data through the official WeChat platform “Vaccine Benefits”. As of that day, Kexing has supplied more than 2.2 billion doses of the new crown vaccine Kellyford to the world (including China), and over 1.8 billion doses have been vaccinated. It is the world’s and China’s largest supply and use of new crown vaccines.

The safety and effectiveness of Chinese vaccines have always been widely recognized. In the past month, all parts of the world, especially developed countries, have intensively announced the acceptance of China’s vaccine travel certification.

Ireland allows passengers who have been fully vaccinated with Coxinghe Sinopharm’s new crown vaccine 14 days later to enter the country with a valid certificate. The Australian medical supplies regulator announced the recognition of the new crown vaccine produced by Kexing, which means that travelers returning to Australia who have received the Kexing vaccine will not need to be quarantined in hotels. The US Centers for Disease Control and Prevention (CDC) previously announced that travelers who have been vaccinated with the new crown vaccine approved by the World Health Organization (WHO), CDC and the US Food and Drug Administration (FDA) can enter the United States. The British government announced that it will approve the use of the new crown vaccines on the emergency use list approved by the WHO from November 22, including two vaccines from Kexing and Sinopharm. The analysis believes that as China’s vaccines such as Kexing obtain vaccine travel certification globally, it is bound to accelerate the recovery of the global economy and personnel exchanges.

China has supplied more than 1.7 billion doses of COVID-19 vaccine overseas

Although the global vaccine supply has exceeded 8 billion doses, the overall vaccination situation is still not optimistic. Italian Prime Minister Draghi, the host country of the G20 summit in 2021, pointed out that although more than 70% of the population in developed countries have received at least one dose of the new crown vaccine, in the world’s poorest regions, this proportion is only about 3%.

See also  London, the lunge of Prince William: "Saving the earth is more important than doing space tourism"

Under such circumstances, China has overcome the reality of its own huge population base and has provided more than 1.7 billion doses of vaccines to more than 110 countries and international organizations. According to data publicly reported by the media recently, China Kexing alone has supplied more than 900 million doses of COVID-19 vaccine to the international community.

In fact, since China announced its participation in the COVAX mechanism in October last year, in addition to exporting finished and semi-finished vaccines, Chinese vaccine manufacturers represented by Kexing are building factories and joint production overseas, and the production model of “nearly quenched the thirst” promotes global vaccines. Fair distribution.

In Asia, local medical institutions in Malaysia and China Kexing cooperate to produce the new crown vaccine. In Indonesia, the local state-owned pharmaceutical company Bio Farma has also reached a joint production agreement with Kexing, which plans to produce 122 million doses of the new crown vaccine.

In Africa, China Kexing has been exporting vaccine raw materials to Egypt since the first half of the year to support Egypt’s local production of the new crown vaccine, making Egypt the first country in Africa with vaccine production capacity.

In Latin America, Coxing and the Brazilian Butantan Institute cooperated to develop vaccines, and also invested in the construction of a vaccine research and development center and a vaccine production plant in Chile to help developing countries in Latin America build a solid vaccine supply chain.

Under the series of actions of joint research and development and joint production, according to the report of The Economist on November 10, as of the end of October, with the help of Chinese vaccines, the vaccination rates in developing countries such as Chile and Cambodia have reached 79% and 77% respectively. %, higher than developed countries such as the West. On the morning of November 17, a new batch of 2 million doses of Coxing’s new crown vaccine from China to Cambodia has been installed and set off. As of that day, the inoculation rate of Cambodia’s new crown vaccine reached 88%.

It is the Chinese government’s commitment to the world to provide 2 billion doses of the new crown vaccine before the end of the year. A group of excellent domestic vaccine development companies represented by Kexing will help the country stick to its commitments and responsibilities, and make China the strongest link in the global vaccine supply chain. (Zhao Qingjian)


0 comment

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy